Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (161-170 of 254) with videos related to

Pageof 26
Sort By:
Human Vaccines & Immunotherapeutics|December 20, 2012
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureusJasdeep S Nanra, Sandra M Buitrago, Shomari Crawford, et al.
Virology|December 19, 2000
Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodiesM D Yeager, M Aste-Amezaga, D R Brown, et al.
Open Forum Infectious Diseases|January 30, 2020
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel <i>Staphylococcus aureus</i> 4-Antigen Vaccine (SA4Ag)C Buddy Creech, Robert W Frenck, Anne Fiquet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 14, 2011
Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumoniaW C Albrich, S A Madhi, P V Adrian, et al.
The Journal of Infectious Diseases|May 11, 2022
A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older AdultsJames Baber, Mark Arya, Yuben Moodley, et al.
Vaccine|February 25, 2015
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adultsMichael Nissen, Helen Marshall, Peter Richmond, et al.
Vaccine|May 9, 2017
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trialOlubukola T Idoko, Robert B Mboizi, Michael Okoye, et al.
Vaccine|July 9, 2022
Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15ALi Hao, Michelle M Kuttel, Neil Ravenscroft, et al.
Virology|May 17, 2005
Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genesKimberly B Johnston, Juanita M Monteiro, Loren D Schultz, et al.
The Journal of Infectious Diseases|December 21, 2021
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza VaccineAnn R Falsey, Edward E Walsh, Daniel A Scott, et al.
Pageof 26

Showing results (161-170 of 254) with videos related to

Sort By:
Pageof 26
Human Vaccines & Immunotherapeutics|December 20, 2012
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureusJasdeep S Nanra, Sandra M Buitrago, Shomari Crawford, et al.
Virology|December 19, 2000
Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodiesM D Yeager, M Aste-Amezaga, D R Brown, et al.
Open Forum Infectious Diseases|January 30, 2020
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel <i>Staphylococcus aureus</i> 4-Antigen Vaccine (SA4Ag)C Buddy Creech, Robert W Frenck, Anne Fiquet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 14, 2011
Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumoniaW C Albrich, S A Madhi, P V Adrian, et al.
The Journal of Infectious Diseases|May 11, 2022
A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older AdultsJames Baber, Mark Arya, Yuben Moodley, et al.
Vaccine|February 25, 2015
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adultsMichael Nissen, Helen Marshall, Peter Richmond, et al.
Vaccine|May 9, 2017
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trialOlubukola T Idoko, Robert B Mboizi, Michael Okoye, et al.
Vaccine|July 9, 2022
Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15ALi Hao, Michelle M Kuttel, Neil Ravenscroft, et al.
Virology|May 17, 2005
Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genesKimberly B Johnston, Juanita M Monteiro, Loren D Schultz, et al.
The Journal of Infectious Diseases|December 21, 2021
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza VaccineAnn R Falsey, Edward E Walsh, Daniel A Scott, et al.
Pageof 26